论文部分内容阅读
目前对PTCA后再狭窄的药理学治疗仍无重大突破,研究必将继续下去。一些有前途的药如凝血酶阻滞剂、平滑肌细胞拮抗剂、生长因子阻滞剂、拟前列环素药、抗血小板膜受体抗体(Gp II_b/III_a)和Von Willebrand因子将投入临床试验,以继续寻找能预防再狭窄的“魔弹”。这种药应至少没有任何副作用,费用较再行PTCA便宜。
Currently there is no major breakthrough in the pharmacological treatment of restenosis after PTCA, and the research will certainly continue. Some promising drugs such as thrombin blockers, smooth muscle cell antagonists, growth factor blockers, prostacyclin, anti-platelet membrane receptor antibodies (Gp II_b / III_a) and Von Willebrand factor will be put into clinical trials, To continue looking for “magic bullet” to prevent restenosis. This drug should have at least no side effects, cheaper than re-PTCA.